Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 5/20 | 0.51 |
| ▸ | DRD4 | P21917 | 4/20 | 0.51 |
| ▸ | AGTR2 | P50052 | 15/20 | 0.51 |
| ▸ | AGTR1 | P30556 | 8/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30164155 | 1.00 | GRM2 (0.51) | GRM2DRD4AGTR2AGTR1DRD2 | |
| SCHEMBL29232145 | 0.93 | GRM2 (0.54) | GRM2DRD4DRD2DRD3 | |
| SCHEMBL30164146 | 0.93 | GRM2 (0.54) | GRM2DRD4DRD2DRD3 | |
| SCHEMBL30164125 | 0.90 | AGTR2 (0.54) | GRM2AGTR2AGTR1 | |
| SCHEMBL29232389 | 0.90 | AGTR2 (0.54) | GRM2AGTR2AGTR1 | |
| SCHEMBL24985229 | 0.88 | GRM2 (0.52) | GRM2DRD4DRD2DRD3 | |
| SCHEMBL30163934 | 0.88 | GRM2 (0.52) | GRM2DRD4DRD2DRD3 | |
| SCHEMBL30164034 | 0.80 | GRM2 (0.64) | GRM2DRD4DRD2DRD3 | |
| SCHEMBL24985228 | 0.77 | LMNA (0.50) | GRM2DRD4 | |
| SCHEMBL30164061 | 0.77 | LMNA (0.50) | GRM2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118159530-A | Compounds for the treatment of pain, in particular neuropathic pain and/or other diseases or disorders associated with AT2R and/or AT2R mediated signalling | 康福治疗有限公司 | 2024-06-07 | — | — | CN | disclosed |
| WO-2023006893-A1 | COMPOUNDS FOR THE TREATMENT OF PAIN, IN PARTICULAR NEUROPATHIC PAIN, AND/OR OTHER DISEASES OR DISORDERS THAT ARE ASSOCIATED WITH AT2R AND/OR AT2R MEDIATED SIGNALING | CONFO THERAPEUTICS N.V. (BE) | 2023-02-02 | — | — | WO | disclosed |